Cladribine
- Generic Name
- Cladribine
- Brand Names
- Litak, Mavenclad
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12ClN5O3
- CAS Number
- 4291-63-8
- Unique Ingredient Identifier
- 47M74X9YT5
Overview
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
Background
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
Indication
For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.
Associated Conditions
- Chronic Lymphocytic Leukemia
- Cutaneous T-Cell Lymphoma (CTCL)
- Hairy Cell Leukemia (HCL)
- Non-Hodgkin's Lymphomas
- Active confirmed by clinical features, confirmed by imaging features relapsing multiple sclerosis (MS)
Clinical Trials
FDA Approved Products
Mavenclad
Manufacturer:EMD Serono, Inc.
Route:ORAL
Strength:10 mg in 1 1
Approved: 2024/02/27
NDC:44087-4000
Cladribine
Manufacturer:Fresenius Kabi USA, LLC
Route:INTRAVENOUS
Strength:1 mg in 1 mL
Approved: 2019/12/31
NDC:63323-140
Cladribine
Manufacturer:Hisun Pharmaceuticals USA, Inc.
Route:INTRAVENOUS
Strength:1 mg in 1 mL
Approved: 2023/02/01
NDC:42658-010
Cladribine
Manufacturer:Hikma Pharmaceuticals USA Inc.
Route:INTRAVENOUS
Strength:1 mg in 1 mL
Approved: 2023/04/19
NDC:0143-9871
Cladribine
Manufacturer:Hisun Pharmaceuticals USA, Inc.
Route:INTRAVENOUS
Strength:1 mg in 1 mL
Approved: 2024/01/01
NDC:42658-010
Singapore Approved Products
MAVENCLAD TABLET 10MG
Manufacturer:NerPharMa S.R.L.
Form:TABLET
Strength:10mg
Online:Yes
Approved: 2019/05/24
Approval:SIN15691P
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath